Study summary

A PI3K pill produced responses in about half of people with relapsed T-cell lymphoma

PRIMO trial, final results · 123 people, phase 2 · Published April 2026, Journal of Clinical Oncology

48.0%response rate

What was tested

Duvelisib, an oral PI3K-delta/gamma inhibitor, for relapsed or refractory peripheral T-cell lymphoma.

What they found

Response rate was 48.0%, with complete responses in 33.3%.
Angioimmunoblastic T-cell lymphoma did best: 62.2% response, median survival 18.1 months.
Median progression-free survival overall was short (3.4 months).

What it means

Strongest in the angioimmunoblastic subtype; now being added to first-line chemotherapy in a US trial.

Targeted Oncology ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.